Simulations Plus Share Holder Equity 2010-2024 | SLP
Simulations Plus share holder equity from 2010 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Simulations Plus Annual Share Holder Equity
(Millions of US $) |
| 2024 |
$182 |
| 2023 |
$170 |
| 2022 |
$178 |
| 2021 |
$166 |
| 2020 |
$156 |
| 2019 |
$38 |
| 2018 |
$32 |
| 2017 |
$26 |
| 2016 |
$23 |
| 2015 |
$20 |
| 2014 |
$15 |
| 2013 |
$14 |
| 2012 |
$15 |
| 2011 |
$14 |
| 2010 |
$13 |
| 2009 |
$11 |
Simulations Plus Quarterly Share Holder Equity
(Millions of US $) |
| 2024-08-31 |
$182 |
| 2024-05-31 |
$181 |
| 2024-02-29 |
$177 |
| 2023-11-30 |
$172 |
| 2023-08-31 |
$170 |
| 2023-05-31 |
$169 |
| 2023-02-28 |
$165 |
| 2022-11-30 |
$180 |
| 2022-08-31 |
$178 |
| 2022-05-31 |
$178 |
| 2022-02-28 |
$173 |
| 2021-11-30 |
$168 |
| 2021-08-31 |
$166 |
| 2021-05-31 |
$165 |
| 2021-02-28 |
$161 |
| 2020-11-30 |
$158 |
| 2020-08-31 |
$156 |
| 2020-05-31 |
$47 |
| 2020-02-29 |
$41 |
| 2019-11-30 |
$39 |
| 2019-08-31 |
$38 |
| 2019-05-31 |
$36 |
| 2019-02-28 |
$34 |
| 2018-11-30 |
$32 |
| 2018-08-31 |
$32 |
| 2018-05-31 |
$31 |
| 2018-02-28 |
$29 |
| 2017-11-30 |
$27 |
| 2017-08-31 |
$26 |
| 2017-05-31 |
$25 |
| 2017-02-28 |
$24 |
| 2016-11-30 |
$23 |
| 2016-08-31 |
$23 |
| 2016-05-31 |
$22 |
| 2016-02-29 |
$20 |
| 2015-11-30 |
$20 |
| 2015-08-31 |
$20 |
| 2015-05-31 |
$20 |
| 2015-02-28 |
$19 |
| 2014-11-30 |
$18 |
| 2014-08-31 |
$15 |
| 2014-05-31 |
$16 |
| 2014-02-28 |
$14 |
| 2013-11-30 |
$14 |
| 2013-08-31 |
$14 |
| 2013-05-31 |
$14 |
| 2013-02-28 |
$14 |
| 2012-11-30 |
$15 |
| 2012-08-31 |
$15 |
| 2012-05-31 |
$16 |
| 2012-02-29 |
$15 |
| 2011-11-30 |
$15 |
| 2011-08-31 |
$14 |
| 2011-05-31 |
$14 |
| 2011-02-28 |
$13 |
| 2010-11-30 |
$12 |
| 2010-08-31 |
$13 |
| 2010-05-31 |
$13 |
| 2010-02-28 |
$11 |
| 2009-11-30 |
$11 |
| 2009-08-31 |
$11 |
| 2009-05-31 |
$11 |
| 2009-02-28 |
$10 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Computer Software |
$0.554B |
$0.070B |
|
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|
